Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, announced its participation in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. CEO Brian M. Culley will engage in a fireside chat with Joseph Pantginis, Managing Director of Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The event will be held at the Nasdaq stock exchange headquarters in New York. Investors can schedule meetings with management through H.C. Wainwright representatives, and a replay of the fireside chat will be available on Lineage's website after the conference.
Lineage Cell Therapeutics (NYSE: LCTX) reported its Q1 2025 financial results and business updates. The company's cash position of $47.9 million is expected to support operations into Q1 2027. Q1 2025 financial highlights include revenues of $1.5 million and a net loss of $4.1 million ($0.02 per share).
Key developments include upcoming 36-month results presentation for RG6501 (OpRegen) Phase 1/2a study at Clinical Trials Summit 2025, initiation of the DOSED clinical study for OPC1 in spinal cord injury patients, and announcement of the 3rd Annual SCI Investor Symposium. The company continues its collaboration with Roche and Genentech on the GAlette Study for geographic atrophy treatment.
Operating expenses were $8.0 million, with R&D expenses at $3.1 million and G&A expenses at $4.9 million.Lineage Cell Therapeutics (NYSE: LCTX) announced that 36-month results from the Phase 1/2a clinical study of RG6501 (OpRegen) will be presented at Clinical Trials at the Summit (CTS) 2025. The study focuses on treating patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The presentation titled "OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 36 Results from the Phase 1/2a Trial" will be delivered by Dr. Christopher D. Riemann from Cincinnati Eye Institute at the conference, scheduled for June 20-21, 2025.
Lineage Cell Therapeutics (NYSE: LCTX), a clinical-stage biotech company focused on allogeneic cell therapies for neurological conditions, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a business update.
Investors can join the call by dialing (800) 715-9871 from the U.S. and Canada. A webcast will be available in the Investors section of Lineage's website, with replay access through May 20, 2025, using conference ID 1789489.
Lineage Cell Therapeutics (LCTX) and the Christopher & Dana Reeve Foundation announce their collaboration for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS), scheduled for June 27, 2025. The event will be fully virtual for the first time to enhance accessibility for individuals with spinal cord injuries.
The symposium aims to unite companies developing SCI treatments with regulators, key opinion leaders, patients, advocacy organizations, and investors. Key discussion topics include:
- Preclinical and clinical SCI treatment approaches
- Drug development processes
- Healthcare disparities in SCI care and outcomes
- Patient perspectives in drug development
- Clinical endpoints and assessment tools
Lineage recently initiated a clinical study of their cell transplant candidate, OPC1, which aims to improve recovery and mobility by replacing cells destroyed after spinal cord injury.
Lineage Cell Therapeutics (NYSE: LCTX) announced its participation in the upcoming Eyecelerator@ Park City 2025 conference, where CEO Brian M. Culley will join a distinguished panel discussing novel drug delivery approaches for glaucoma and retina treatments.
The panel, titled 'I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina', will feature representatives from REGENXBIO Inc., Regenerative Patch Technologies, and Neurotech Pharmaceuticals. The session is scheduled for May 2, 2025, from 12:30pm to 1:30pm MDT at the Grand Hyatt, Deer Valley, Utah.
The discussion will be chaired by Dr. Allen C. Ho, Eyecelerator Retina Program Director and Wills Eye Hospital Attending Surgeon. The event is sponsored by the American Academy of Ophthalmology (AAO), and the panel presentation will be made available on Lineage's website after the conference.
Lineage Cell Therapeutics (LCTX) reported its Q4 and full year 2024 financial results, highlighting significant progress across multiple programs. The company's lead asset OpRegen, developed in collaboration with Roche and Genentech, received RMAT designation from FDA for geographic atrophy treatment.
Financial highlights include:
- Q4 2024 revenues of $2.9M (up from $2.1M in Q4 2023)
- Full year 2024 revenues of $9.5M (up from $8.9M in 2023)
- Q4 net loss of $3.3M ($0.02 per share)
- Full year net loss of $18.6M ($0.09 per share)
- Cash position of $47.8M as of December 31, 2024
The company completed two financings totaling $44M in gross proceeds, with potential for additional $36M from warrant exercises. Current cash runway extends into Q1 2027. Operating expenses decreased to $31.0M in 2024 from $33.7M in 2023, reflecting improved operational efficiency.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on allogeneic cell therapies for neurological conditions, has scheduled its fourth quarter and full year 2024 financial results announcement for March 10, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 from the U.S. and Canada, requesting the 'Lineage Cell Therapeutics Call'. A webcast will be available in the Investors section of the company's website, with replay access through March 17th, 2025 (conference ID: 6707203).
Lineage Cell Therapeutics (NYSE: LCTX) has initiated the DOSED clinical study to evaluate a novel delivery device for OPC1, their investigational stem cell-derived transplant for spinal cord injury (SCI). The study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System) for delivering OPC1 to injury sites.
The DOSED study will include both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) SCI patients, marking the first time OPC1 will be tested in chronic cases. OPC1 has already demonstrated a strong safety profile in two previous clinical trials: a five-patient Phase 1 safety trial in acute thoracic SCI with 13+ years of follow-up, and a 25-patient Phase 1/2a trial in subacute cervical SCI with 7+ years of follow-up.
The new delivery system allows administration over several minutes without interrupting patient ventilation and is compatible with a new immediate-use formulation of OPC1. The first study site will be UC San Diego Health.